Blog Read the latest perspectives from our team of subject matter experts and others The Trust Fall: Building Successful & Diverse Trials Outside the U.S.As the U.S. ramps up for release of the latest COVID-19 vaccine booster, the Centers for Disease Control and Prevention (CDC) recommends that all Americans aged 6 months and… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Diversity & Inclusion Drug Development KOL Engagement Medical Devices Provider Data Research Post Industries:Commercialization Medical Devices Payors Pharmaceutical & Biotechnology Provider Data Research Artificial IntelligenceBalancing Creativity and Accuracy in Artificial IntelligenceIn the realm of AI, balancing creativity and accuracy is a critical consideration, especially when developing AI systems for business applications. While creativity adds novelty and innovation to outputs,… Continue reading → Read the articleno CommercializationDrug DevelopmentWhat Payer Trends Can Tell Us About Medication AdherenceOne of the most important aspects of monitoring payer trends is getting an accurate picture of patient utilization. Understanding which treatments are being utilized, by whom, and for what… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentImproving Oncology Clinical Trials for Accelerated ApprovalIn March of 2023, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design specific… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentWhy Drug Approvals and Development Hinge on DiversityThe success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentKOL EngagementBuilding an Exclusive Strategy with Inclusive HCPsAs healthcare providers (HCPs) are increasingly relying on evidence-based data and clinical guidelines, life science organizations must shift their focus to enabling HCPs in the effective adoption of these medicines.… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentA Lesson in History: Assessing Trial Performance Data for Future Trial DesignClinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. Performance data on principal investigators and clinical trial sites provides invaluable insights to… Continue reading → Read the articleno‹12345›»
